Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Executive Summary
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
You may also be interested in...
Biotheryx’s Initial Alliance Pairs With Incyte On Targeted Protein Degradation
Biotheryx will deploy its PRODEGY platform to discover candidates against novel cancer targets selected by Incyte. The deal occurred the same day as a Merck/Proxygen protein-degradation alliance.
Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies
Private Company Edition: Alexis Borisy and his Curie.Bio co-founders will invest $5m-$7m to help companies get to lead optimization within 12-18 months. Also, Feng Zhang-founded Aera launched with $193m, Hexagon Bio raised a $77.3m series B round and Halda emerged with $76m.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.